NCODA Logo

NEWS

Advancements in Patient-Centered Care

Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

OKLAHOMA RECOGNIZES PHARMACISTS AS ESSENTIAL COMMUNITY PROVIDERS

June 10, 2022

FOR IMMEDIATE RELEASE STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org        OKLAHOMA RECOGNIZES PHARMACISTS AS ESSENTIAL COMMUNITY PROVIDERS NCODA applauds the recent efforts of the Oklahoma Legislature that passed HB 2322. This law recognizes pharmacists as Essential Community Providers […]
read more

NCODA Announces New Legislative & Policy Advisory Committee (LPAC) Member, Barbara McAneny, MD, FASCO, MACP

June 2, 2022

NCODA is proud to announce that Barbara McAneny, MD, FASCO, MACP will be joining our Legislative & Policy Advisory Committee (LPAC). Dr. McAneny is the CEO of New Mexico Oncology Hematology Consultants. Dr. McAneny was also elected by the American Medical Association House of Delegates and served as AMA President from 2018 – 2019. “NCODA […]
read more

WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS

April 20, 2022

April 20, 2022 FOR IMMEDIATE RELEASE   STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS The state of Washington wrapped up their legislative session with a huge victory for patients. Senate […]
read more

NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options

April 14, 2022

NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options “NCODA Informatics Initiative Powered by VisualStrata” Helps Attract Clinical Trials for Oncology Practices and Bridges the Gap with Pharmaceutical Organizations San Diego, CA and Cazenovia, NY April 14, 2022 – XIFIN has partnered with NCODA, Inc., a globally recognized association that develops unique […]
read more

OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS

April 6, 2022

FOR IMMEDIATE RELEASE April 6, 2022 STATEMENT FROM NCODA LEGISLATIVE & POLICY ADVISORY COMMITTEE Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison (919) 903-2057 kevin.scorsone@ncoda.org www.ncoda.org OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS CAZENOVIA, NY – NCODA is proud to share the news that the Ohio House unanimously (86 to 0) […]
read more

NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians

March 29, 2022

FOR IMMEDIATE RELEASE  March 29, 2022 MEDIA CONTACT: Katie Edmiston Katie.Edmiston@NCODA.org 813-843-1629   NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians   CAZENOVIA, NY – NCODA, a professional association dedicated to empowering the medically-integrated oncology community through leadership, quality standards, and best practices, is now certified by the Accreditation Council for […]
read more

Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies

March 24, 2022

The challenges associated with medication adherence and the negative impacts of non-adherence have been well documented. Medication adherence affects many aspects of public health, including, but not limited to, quality of life, patient outcomes, and overall healthcare costs.1 It is generally accepted that adherence rates of more than 80% are needed for optimal therapeutic efficacy.2 […]
read more

Oral Oncolytic Care Plans in Medically Integrated Dispensing Pharmacies

March 24, 2022

The development and utilization of oral oncolytics has steadily increased over the past 20 years. There are over 800 new oncology therapies in the drug development pipeline, 25%-35% of which are oral agents.1 The use of oral oncolytics presents unique challenges to patient safety compared to intravenous cancer treatments. As oral oncolytics are self-administered, it […]
read more

First-Of-Its-Kind Oncology State Legislation Tracking Tool

March 15, 2022

FOR IMMEDIATE RELEASE March 15, 2022 MEDIA CONTACT: Stephen Ziter Stephen.Ziter@ncoda.com 518-867-5001   First-Of-Its-Kind Oncology State Legislation Tracking Tool NCODA Launches a New Comprehensive Resource to Allow Oncology Healthcare Professionals to Stay Updated on the Latest in Relevant Policy/Legislation in all 50 States CAZENOVIA, NY – Today, NCODA announces the launch of its new and […]
read more

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia

March 1, 2022

– VONJO is the First Approved Therapy to Specifically Address the Needs of Adult Cytopenic Myelofibrosis Patients – NDA Approved Under Priority Review – Approval Triggers $60 Million Payment from DRI Healthcare Trust – CTI to Host Conference Call Tomorrow at 8:00 a.m. ET SEATTLE, Feb. 28, 2022 /PRNewswire/ — CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. […]
read more

RESOURCES

Cost Avoidance Waste Tracker

Positive Quality Interventions

PQI in Action

OCE Sheets

IVE Sheets

Treatment Support Kits

PQI Podcast

Members

Member Resources

OPTA

Committees

Member Login

Events

Webinars

Spring Forum

Oncology Institute

PSO Annual Meeting

Fall Summit

contact@ncoda.org

315-655-4640

P.O. Box 468
Cazenovia, NY 13035

NCODA Logo

NCODA is a 501(c)(3) Organization